Shuttle Pharmaceuticals Holdings, Inc. acquires United Dogecoin Inc. (2026)

Deal facts

Buyer: Shuttle Pharmaceuticals Holdings, Inc.
Target: United Dogecoin Inc.
Deal value: Not disclosed
Announced: 7 May 2026
Status: Completed
Sector: Healthcare
Country: United States
Consideration: shares, earn-out

Sources

SEC_EDGAR_8K

What we know

Weekly digest

Join Exit Mode Insider

Ten deal briefs a week, founder commentary, and the patterns worth paying attention to.

Join Exit Mode Insider, £12/mo

Deal timeline

1 update

6 May 2026CompletedClosed
Shuttle Pharmaceuticals Holdings, Inc. completes acquisition of United Dogecoin Inc.
Item 1.01 Entry Into A Material Definitive Agreement. Merger Agreement General Description of the Merger Agreement On May 6, 2026 (the “ Closing Date ”), Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (“ Shuttle ” or “ Acquiror ”), completed its previously announced merger pursuant to an Agreement and Plan of Merger (the “ Merger Agreement ”), entered into on April 30, 2026 by and
Source

OpinionExit Mode editorial

We see a deal structure that defies conventional sector logic. Shuttle Pharmaceuticals Holdings, Inc. has completed its acquisition of United Dogecoin Inc. This transaction, announced on 7 May 2026, pairs a healthcare entity with a digital asset firm. The absence of a disclosed cash value and the reliance on shares alongside an earn-out mechanism suggest a high degree of uncertainty regarding the target's standalone valuation. In the UK market, we often see such structures used to bridge valuation gaps when buyer and seller cannot agree on current worth.

The consideration mix is the most critical element here for the SME founder reading this. By accepting shares and an earn-out, the sellers of United Dogecoin Inc. have effectively tied their future wealth to the combined entity's performance. This is not a clean exit. It introduces significant change-of-control risks and performance contingencies that can drag on for years. If the buyer struggles to integrate the crypto business or if the regulatory environment shifts, the earn-out targets may never be met. The buyer assumes the risk of integration, yet the seller retains the risk of non-payment if milestones are missed.

We must also consider the regulatory context. While both parties are US-based, a cross-sector deal of this nature invites scrutiny from competition authorities. The combination of a pharmaceutical firm and a cryptocurrency entity could trigger anti-trust thresholds or require specific regulatory clearance depending on how the businesses are classified. For the founder, the lack of cash upfront means you are betting on the buyer's ability to execute a strategy that spans two vastly different industries. The deal is marked as completed, but the commercial reality for the former owners remains contingent on future metrics.

Your immediate action this week is to audit your own exit term sheets for any earn-out clauses. Ensure that the performance metrics triggering payment are entirely within your control or clearly defined to prevent the buyer from manipulating results. If a deal offers only shares and conditional cash, demand a minimum guaranteed floor or a shorter earn-out period to limit your exposure to post-closing volatility.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2026 deals More strategic acquisition deals More from Shuttle Pharmaceuticals Holdings, Inc.All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

29 April 2026CompletedHealthcare

MedPal AI plc to acquire Remedi Solutions Limited

MedPal AI plc and Remedi Solutions Limited entered the Exit Mode archive.

Buyer: MedPal AI plc
Target: Remedi Solutions Limited
Deal value: GBP 310,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United Kingdom deals

27 April 2026CompletedHealthcare

BIOMARIN PHARMACEUTICAL INC to acquire Amicus

BIOMARIN PHARMACEUTICAL INC and Amicus entered the Exit Mode archive.

Buyer: BIOMARIN PHARMACEUTICAL INC
Target: Amicus
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

22 April 2026CompletedHealthcare

Telomir Pharmaceuticals, Inc. to acquire TELI Pharmaceuticals, Inc.

Telomir Pharmaceuticals, Inc. and TELI Pharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Telomir Pharmaceuticals, Inc.
Target: TELI Pharmaceuticals, Inc.
Deal value: USD 34,389,710
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

15 April 2026CompletedHealthcare

GSK plc to acquire 35Pharma Inc.

GSK plc has agreed to acquire 35Pharma Inc., a Canadian biopharmaceutical company, for an equity value of USD 950 million. The transaction was structured as a strategic…

Buyer: GSK plc
Target: 35Pharma Inc.
Deal value: USD 950,000,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals Canada deals

13 April 2026Firm intentionHealthcare

EKF Diagnostics Holdings plc to acquire Beep Insights AB

EKF Diagnostics Holdings plc has agreed to acquire Beep Insights AB, a Swedish company operating within the diagnostics sector. The transaction is structured as a strate…

Buyer: EKF Diagnostics Holdings plc
Target: Beep Insights AB
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals Sweden deals

Buyer history